Valishetti, Manoj Kumar
To evaluate the safety and efficacy of amlodipine and chlorthalidone in combination with telmisartan in hypertensive patients attending tertiary care centre, Telangana - Vol.14(11) - M P Innovare Academic Sciences Pvt Ltd 2022 - 37-42p.
Objective:The main objective of this study is to evaluate and compare the effects of both treatments on systolic and diastolic blood pressure in 4th, and 8th weeks with baselineMethods:A prospective, comparative, Open-label, and parallel-group clinical study was conducted in out patient's department of general medicine at Osmania general hospital. 120 patients were randomly allocated into 2 groups. Group 1 with 60 patients received Tab: Telmisartan 40 mg+Amlodipine 5 mg once daily, and Group 2 with 60 patients received Tab: Telmisartan 40 mg+ Chlorthalidone 6.25 mg once daily for a period of 8 w. Follow-up was done in the 4th week and 8th week to evaluate the safety and efficacy in hypertensive patients.Results: The differences in the SBP, DBP, and HR in group A (P value<0.001) and group B (P value<0.001) at the 4th week and 8th week follow-up periods with baseline value (0 w) were statistically significant as P value<0.05.Conclusion: The combination of telmisartan plus amlodipine is equally effective as the combination of telmisartan plus chlorthalidone in decreasing SBP, DBP, HR, and MAP. No major adverse drug reactions were noted during the study period.
PHARMACEUTICS
To evaluate the safety and efficacy of amlodipine and chlorthalidone in combination with telmisartan in hypertensive patients attending tertiary care centre, Telangana - Vol.14(11) - M P Innovare Academic Sciences Pvt Ltd 2022 - 37-42p.
Objective:The main objective of this study is to evaluate and compare the effects of both treatments on systolic and diastolic blood pressure in 4th, and 8th weeks with baselineMethods:A prospective, comparative, Open-label, and parallel-group clinical study was conducted in out patient's department of general medicine at Osmania general hospital. 120 patients were randomly allocated into 2 groups. Group 1 with 60 patients received Tab: Telmisartan 40 mg+Amlodipine 5 mg once daily, and Group 2 with 60 patients received Tab: Telmisartan 40 mg+ Chlorthalidone 6.25 mg once daily for a period of 8 w. Follow-up was done in the 4th week and 8th week to evaluate the safety and efficacy in hypertensive patients.Results: The differences in the SBP, DBP, and HR in group A (P value<0.001) and group B (P value<0.001) at the 4th week and 8th week follow-up periods with baseline value (0 w) were statistically significant as P value<0.05.Conclusion: The combination of telmisartan plus amlodipine is equally effective as the combination of telmisartan plus chlorthalidone in decreasing SBP, DBP, HR, and MAP. No major adverse drug reactions were noted during the study period.
PHARMACEUTICS